Abilify MyCite, a combination of Otsuka's Abilify and Proteus Digital Health's ingestible sensor, provides the ability to track the ingestion of medication and transmits information to a mobile app that can be shared by the patient with physicians and caregivers. Will this digital pill be the secret to increasing adherence and compliance among those with schizophrenia and bipolar disease, who often struggle with these issues? And if this digital pill demonstrates positive benefits, what's next? Certainly, a digital pill that has positive improvement on adherence would attract the attention of drug manufacturers worldwide. From there, it doesn't seem a big leap to think of digitizing medications for serious illnesses impacting young children and teens who may need caregiver reminders to stay compliant. Would there be benefit in tracking ingestion of treatments for dementia or Alzheimer's Disease? Imagine digital medicine that could detect large changes in one's vital signs, providing early warning of stroke, heart attack, or seizures for those at high risk. Depending on the success of Abilify MyCite, we could be on the verge of a digital medicine explosion. I leave for another day the discussion about how we'll manage patient privacy and who will become responsible for monitoring and securing the information created. Today, let's celebrate a first in digital medicine.
FDA announced the approval of Otsuka Pharmaceutical's Abilify MyCite as the first drug authorised in the US with a digital ingestion tracking system